Hematology/oncology and stem cell therapy最新文献

{"title":"Cytomegalovirus infection in pediatric haploidentical stem cell transplantation.","authors":"Abdulrahman AlSweed, Suliman Aljumaah, Hawazen AlSaedi, Hibah Alruwaisan, Raghad Alhuthil, Sami Al-Hajjar","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00044","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00044","url":null,"abstract":"<p><strong>Background: </strong>Human cytomegalovirus (CMV) is a major source of morbidity and mortality in pediatric hematopoietic stem cell transplantation (HSCT). CMV replication is mainly controlled by T-cell-mediated immunity. Despite treatment, CMV reactivation continues to have a significant adverse impact on post-transplant outcomes. In this study, we examine the clinical aspects and risk factors for CMV reactivation and disease, and the effect of therapeutic interventions in pediatric patients who underwent HSCT.</p><p><strong>Methods: </strong>This retrospective, single-center study included pediatric patients who underwent haploidentical HSCT at King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia, from 2013 to 2018.</p><p><strong>Results: </strong>A total of 94 HSCT recipients were included: 46 (48.94%) females and 48 (51.06%) males, with a median age of 5 years [interquartile range (IQR): 1.2-8.7]. As for donors, 57 (60.64%) were males and 37 (39.36%) were females, with a median age of 30.7 years (IQR: 23.0-35.3). CMV reactivation occurred in 52 (55.32%) of the HSCT patients. The overall mortality rate was 12.77% (12/94), and of those, 83.33% (10/12) were CMV positive. However, no patient developed CMV pneumonitis, gastritis, or colitis, and CMV was not identified as the direct cause of death. Regarding CMV risk factors, higher recipient age and the presence of acute graft-versus-host disease were significantly associated with CMV reactivation (P < 0.05).</p><p><strong>Conclusion: </strong>Preventing CMV infection significantly impacts the post-transplant course, especially in the setting of mismatched donors. This study showed that preventing CMV by preemptive therapy revealed an undetectable rate of 78.85%. Current polymerase chain reaction (PCR)-directed surveillance and prophylaxis have lowered the incidence of CMV disease and persistent DNAemia.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 2","pages":"86-92"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144736547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse events associated with infusion of stem cell products in pediatric blood and marrow transplant recipients.","authors":"Saadiya Khan, Mujtaba Al-Yaseen, Khawar Siddiqui, Hawazen AlSaedi, Ali Al-Ahmari, Abdullah Al-Jefri, Ibrahim Ghemlas, Awatif AlAnazi, Mouhab Ayas","doi":"10.4103/hemoncstem.HEMONCSTEM-D-23-00055","DOIUrl":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-23-00055","url":null,"abstract":"<p><strong>Background: </strong>Adverse events (AEs) associated with blood product transfusions have been extensively studied, whereas those associated with cellular therapy products (CTPs) seen in children undergoing hematopoietic stem cell transplantations are not commonly documented and analyzed.</p><p><strong>Patients and methods: </strong>Herein, we retrospectively studied pediatric patients below the age of 14 years for AEs within 48 h of CTP infusions while evaluating them in the context of pre-existing allergies, transplant-related parameters, and the outcome of the events. Data from 656 consecutive pediatric transplants at our institution from 2016 to 2020 was analyzed. Observed events were classified and graded as per CTC AE (Version 5.0) and consolidated into a single binary variable. The incidence of AEs recorded during the first 48 h of infusion was 4.9% (n = 32).</p><p><strong>Results: </strong>Hypertension was the most common AE observed in 28 episodes, followed by hematuria (four episodes). Occurrence of AEs was found to be significantly associated with older age of the recipients (P = 0.048), hemoglobinopathies as a primary indication for transplant (P = 0.016), allogeneic graft type (P = 0.039), bone marrow as a source of the stem cells (P = 0.006), and documented substance allergies prior to infusion (P = 0.001). We did not find any association between children with AEs and the toxicity of dimethyl sulfoxide with the number of bags used for transfusion (single: 17 [56.7%] vs. multiple: 13 [43.3%], P value: NS).</p><p><strong>Conclusion: </strong>In conclusion, our patients had low rates of AEs with CTPs. These AEs vary with allergenicity and need to be monitored with similar caution as regular blood products.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"9-13"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Framework for Patient Advocacy in Hematopoietic Cell Transplantation (HCT): An Overview from the Worldwide Network for Blood and Marrow Transplantation.","authors":"Riad El Fakih, Cristobal Frutos, Carmem Bonfim, Daniel Weisdorf, Mickey Koh, Sebastian Galeano, Kim Sadler, Ahmed Amro, Damiano Rondelli, Dietger Neiderwiser, Mahmoud Aljurf","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00054","DOIUrl":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00054","url":null,"abstract":"<p><p>Hematopoietic cell transplantation is a complex procedure that often places significant emotional, financial, and social stress on patients, their families, and caregivers. The process is demanding, requiring extended hospital stays, frequent appointments, and ongoing posttransplant care. These challenges are compounded by uncertainty surrounding the outcome as well as financial burden. In this review, we underscore the importance of establishing comprehensive support systems for patients, their families, and caregivers throughout this journey. Providing adequate education and counseling with resources can play a vital role in minimizing the impact on patients and their families.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SNHG14 lncRNA as a Prognostic Biomarker in Adult Non-M3 AML Patients.","authors":"Saba Seifpour, Mina Soufi Zomorrod, Amir Atashi, Sanaz Khaseb, Fatemeh Tavangar, Mahdi Kohansal Vajari, Mohammad Ahmadvand","doi":"10.4103/hemoncstem.hemoncstem-D-24-00012","DOIUrl":"https://doi.org/10.4103/hemoncstem.hemoncstem-D-24-00012","url":null,"abstract":"<p><strong>Background and objectives: </strong>Acute myeloid leukemia (AML) is one of the most common blood malignancies in adults, characterized by the involvement of hematopoietic myeloid progenitors. Numerous studies have demonstrated the involvement of long noncoding RNAs (lncRNAs) in AML pathogenesis. This study aimed to investigate the expression profile of lncRNA small nuclear RNA host gene 14 (SNHG14) and its role in the pathogenesis, clinical features, and prognosis of adult non-M3 AML.</p><p><strong>Materials and methods: </strong>The expression level of SNHG14 was evaluated in bone marrow (BM) samples obtained from 50 adult non-M3 AML patients and 49 healthy controls using Quantitative Reverse Transcription-Polymerase Chain Reaction. We also investigated the correlation between clinicopathological characteristics and SNHG14 expression levels in AML patients.</p><p><strong>Results: </strong>The expression level of SNHG14 was significantly decreased in the BM tissues of adult non-M3 AML patients compared to healthy controls. Patients with low SNHG14 expression were associated with poor overall survival, while no correlation was found between low SNHG14 expression and relapse-free survival.</p><p><strong>Conclusion: </strong>Our findings suggest that SNHG14 expression could serve as a potential biomarker for prognosing adult non-M3 AML patients. Furthermore, SNHG14 may offer insights into novel therapeutic targets for this subset of AML patients.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"21-28"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Marking over a century of Auer rods: An illustrated review of acute promyelocytic leukemia.","authors":"Ruah Alyamany, Ayman Saad, Ahmad Alotaibi, Marwan Shaheen, Mansour Alfayez","doi":"10.4103/hemoncstem.hemoncstem-D-25-00007","DOIUrl":"https://doi.org/10.4103/hemoncstem.hemoncstem-D-25-00007","url":null,"abstract":"<p><p>In 1903, Dr. John Auer first observed needle-like rods in what he initially mistook for lymphocytes from a patient with fever, coagulopathy, and splenomegaly. Later discovered in myeloblasts, these \"Auer rods\" emerged as a defining feature of myeloid malignancies. Among them, acute promyelocytic leukemia (APL), recognized as a distinct clinical entity in 1957, was once considered the most lethal acute leukemia due to its severe coagulopathy and alarmingly high early mortality rate. However, landmark breakthroughs, particularly the introduction of all-trans retinoic acid in the 1980s and arsenic trioxide in the 1990s, transformed APL into the most curable form of acute leukemia, provided that treatment begins early. This illustrated review highlights over a century since Auer rods were first identified, offering a concise, visually guided overview of APL's epidemiology, clinical presentation, and diagnostic strategies. We explore modern and practical therapeutic approaches, emphasize risk-adapted treatments, and address major complications, including differentiation syndrome, coagulopathy, and central nervous system involvement. The remarkable evolution of APL-from a highly fatal disease to the most treatable leukemia-highlights how our understanding of disease pathophysiology and biology can transform treatment strategies and improve patient outcomes.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"5-8"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of High-Flow Nasal Cannula Therapy in Pediatric Hematology/Oncology Patients Admitted to the Pediatric Intensive Care Unit with Acute Respiratory Failure.","authors":"Tareq Alayed, Muhammad Qadri, Abdullah Alturki, Fahad Aljofan, Moath Alabdulsalam, Tariq Alofisan, Munirah Alshalawi, Heba Jaamour, Mohammed Hady Albitar, Razan Adib Alsawadi","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00048","DOIUrl":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00048","url":null,"abstract":"<p><strong>Background: </strong>High-flow nasal cannula (HFNC) therapy is an essential tool for managing acute respiratory failure (ARF) in pediatric patients with hematological and oncological conditions. This study aimed to evaluate the HFNC failure rate and identify factors associated with HFNC failure in pediatric hematology/oncology patients admitted to the pediatric intensive care unit (PICU) with ARF.</p><p><strong>Methods: </strong>This is a retrospective cohort study that included 200 pediatric hematology/oncology patients aged 0-14 years with ARF who underwent HFNC. All patients were admitted to the PICU at the King Fahad National Center for Child Cancer in Saudi Arabia from January 2018 to December 2020.</p><p><strong>Results: </strong>The patient cohort had a median age of 3 years (interquartile range [IQR]: 1.3-7.0), and (61.5%) of patients were males. The key indications for HFNC were pneumonia (48.0%), sepsis (46.0%), and cardiac failure (18.0%). The median duration of HFNC was 36 h (IQR: 20-68), and the median PICU length of stay was 6 days (IQR: 4-16). HFNC failure rate was (27.0%). Air leaks were reported in (2.5%) of patients. The PICU mortality was 29.5% (59/200), including 40 patients (67.8%) with HFNC failure. Required intubation within 48 h was observed in 13.0% (26/200) of patients. Multivariable analysis revealed that the initial pH (p = 0.030), shorter HFNC duration (p < 0.001), cardiac failure (p = 0.009), and sepsis (p = 0.041) were predictors of HFNC failure.</p><p><strong>Conclusion: </strong>The HFNC failure rate in this study was 27%, which is within the range of other studies. Thus, HFNC is an acceptable treatment option for pediatric hematology/oncology patients with ARF. However, further investigation is required.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"29-34"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144063927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival and Chemotherapy Response in Metastatic Lung Carcinoids: Insights from the National Cancer Database.","authors":"Niraj Neupane, Sumeet K Yadav, Elham Moases Ghaffary, Scott R Houle, Umesh Ghimire, Binita Neupane, Sangharsha Thapa, Omid Mirmosayyeb, Zeni Kharel, Chengu Niu, Utsav Joshi","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00001","DOIUrl":"https://doi.org/10.4103/hemoncstem.HEMONCSTEM-D-24-00001","url":null,"abstract":"<p><strong>Background: </strong>Metastatic lung carcinoids (MLCs) represent a rare subset of lung cancers with distinct histologic subtypes. Survival outcomes and prognostic factors have not been well-studied in the real-world setting. This study investigates the impact of various treatments, including chemotherapy, hormonal therapy, and no treatment, on the overall survival (OS) of patients with typical and atypical MLC.</p><p><strong>Methods: </strong>Patients with MLC between 2010 and 2020 were included from the National Cancer Database based on histologic codes ICD-O-3 8240/3 and 8249/3. Kaplan-Meier curves and multivariate Cox proportional hazard regression were used to compare OS and evaluate prognostic factors.</p><p><strong>Results: </strong>The median age at diagnosis was 68 and 69 years for atypical and typical MLC, respectively. The 3-year OS for the atypical MLC cohort was 22.11%, and for typical MLC was 41.94% (P < 0.001). In the atypical MLC cohort, chemotherapy showed a nonsignificant benefit in OS (hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.73-1.05; P = 0.21), whereas hormonal therapy was associated with significantly improved OS (HR, 0.72; 95% CI, 0.52-0.98; P =0.04). However, in the typical MLC cohort, chemotherapy was associated with adverse OS (HR, 2.15; 95% CI, 1.85-2.49; P < 0.0001), and hormonal treatment showed better, albeit nonsignificant OS (HR, 0.84; 95% CI, 0.67-1.05; P = 0.13).</p><p><strong>Conclusion: </strong>There is a notable difference in survival outcomes between typical and atypical MLC based on the treatment strategies. While hormonal therapy shows improvement in the OS, the effectiveness of chemotherapy varies depending on the histologic subtype. These findings emphasize the necessity for personalized therapeutic approaches based on the specific characteristics of MLC, ultimately contributing to improved patient outcomes in this challenging oncologic group. Further research is warranted to validate and expand upon these observations.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"18 1","pages":"14-20"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post hematopoietic stem cell transplant (HSCT) outcomes in pediatric intensive care unit, experience from a referral center for cellular therapy and hematopoietic stem cell transplantation.","authors":"Hussain AlAbdullah, Fawaz Alanzi, Raghad Alhuthil, Tahani Alshaibani, Nourah AlBeeshi, Ali Alqahtani, Moath Alabdulsalam, Tareq Alayed, Abdullah Alturki, Tariq Alofisan, Fahad Aljofan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00022","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00022","url":null,"abstract":"<p><strong>Background: </strong>Patients who underwent hematopoietic stem cell transplantation (HSCT) are considered at high risk for pediatric intensive care unit (PICU) admission. Therefore, this study aimed to assess outcomes and mortality-related risk factors among pediatric HSCT recipients admitted to the PICU.</p><p><strong>Methods: </strong>This retrospective cohort study was conducted at a Saudi Arabian tertiary care center and involved pediatric patients (aged 4 weeks to 14 years) who underwent HSCTs between January 2015 and December 2019 and were admitted to the PICU.</p><p><strong>Results: </strong>Of the 173 pediatric HSCT recipients admitted to the PICU, 65.3% were admitted for respiratory failure. Graft-versus-host disease and chronic infections affected 48.6% and 71.7% of the cases, respectively. Pulmonary hemorrhage and veno-occlusive disease occurred in 15.0% and 32.4% of the patients, respectively. Ventilation and inotropic support were administered to 79.8% and 41.0%, respectively. Acute kidney injury (AKI) occurred in 47.4% of the patients, of which 23.2% required continuous renal replacement therapy/hemodialysis. The PICU survival rate was 59.0% (102/173), and the mortality rate was 41.0% (71/173). In the univariate analysis, chronic infection, pulmonary hemorrhage, ventilation, inotropic support, AKI, higher PRISM III score, and prolonged PICU stay were associated with mortality (P < 0.05). In the multivariable analysis, only prolonged PICU stay (P = 0.016), AKI (P = 0.040), inotropic support (P < 0.001), and ventilation (P = 0.017) showed potential association with mortality.</p><p><strong>Conclusion: </strong>Early recognition and targeted interventions for these complications are crucial for improving outcomes in this vulnerable population. More research is needed to validate these findings and optimize care practices for HSCT recipients in the PICU setting.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"227-232"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of plerixafor on the hemostatic system in patients undergoing stem cell mobilization.","authors":"Özge Koç, Özlem Doğan, Uğur Şahin, Ekin Kircali, Derya Koyun, Mutlu Arat, Muhit Özcan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00006","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00006","url":null,"abstract":"<p><p>Despite numerous reports on the procoagulant activities of G-CSF, the effect of plerixafor on the hemostatic system is not clearly understood. This study aims to evaluate the effects of plerixafor on the hemostatic system when used for autologous stem cell mobilization (ASCM) for poor mobilizers (PM) with lymphoma and multiple myeloma. Patients who were performed ASCM with plerixafor in combination with GCSF were prospectively enrolled. Cohort A included patients mobilized with G-CSF whereas Cohort B included patients mobilized with G-CSF + plerixafor. Blood samples were obtained before the mobilization regimen and just before apheresis. CBC, coagulation tests, CRP, protein C and S, vWF antigen, and factors VIII and XII were studied. Cohort A (n= 30) of which 9 received chemotherapy + G-CSF. Factor VIII, INR, vWF antigen, and CRP significantly increased after G-CSF compared to baseline. Decreases in protein C and S were significant (p<0.001; p=0.005). In cohort B (n=15) no significant changes were observed in coagulation parameters Factor levels, protein C and S before and after the plerixafor. Fibrinogen decreased slightly after plerixafor administration (4.2773±2.2125 vs. 3.6987±1.5062; p=0.02). remained unchanged. In conclusion the addition of plerixafor to G-CSF did not exert further significant procoagulant effects.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"211-218"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence, distribution, and patient characteristics of childhood cancer in Jordan: an updated population-based study.","authors":"Ranya Baddourah, Dana Baddourah, Dalia Alsweedan, Mahmoud Al Sheyyab, Omar F Nimri, Suleiman Alsweedan","doi":"10.4103/hemoncstem.HEMONCSTEM-D-24-00025","DOIUrl":"10.4103/hemoncstem.HEMONCSTEM-D-24-00025","url":null,"abstract":"<p><strong>Background and objectives: </strong>The most recent study on pediatric cancer epidemiology in Jordan was published in 2003. This study aims to provide updated epidemiological data for local clinicians, policymakers, and international physicians interested in Middle Eastern patient populations.</p><p><strong>Materials and methods: </strong>We analyzed data from the Jordanian National Cancer Registry for pediatric patients (ages 0-18) diagnosed between 2000 and 2017, classified according to the International Classification of Childhood Cancer, third edition.</p><p><strong>Results: </strong>Our cohort comprised 7639 patients. The mean age at diagnosis was 8.68 years, with a male-to-female ratio of 1.4 and an annual incidence rate of 191 per million population. We identified significant differences in cancer distribution between Jordan and neighboring Middle Eastern countries, as well as regional discrepancies in the number of diagnosed childhood cancer cases. A comparison of cancer incidence between 1996-1998 and 2000-2017 in Jordan was conducted. Our findings align with established trends, such as the correlation between the male-to-female cancer incidence ratio and GDP per capita.</p><p><strong>Conclusion: </strong>This study provides the latest organized and accessible data on childhood malignancies in Jordan.</p>","PeriodicalId":516321,"journal":{"name":"Hematology/oncology and stem cell therapy","volume":"17 4","pages":"233-238"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143019752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}